Myriad Genetics
MYGN | NASDAQ
$5.57
-$0.09 (-1.59%)
At close: Nov 16, 2026, 4:00 PM ET
$5.57
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 5:56 PM ET
Myriad Genetics Company Profile
Company profile explainedCompany Profile
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Key Executives
| Name | Position |
|---|---|
| Samraat S. Raha | President, Chief Executive Officer & Director |
| Benjamin R. Wheeler | Chief Financial Officer & Principal Accounting Officer |
| Jennifer L. Fox | Chief Legal Officer |
| Mark S. Verratti | Chief Operating Officer |
| Raj Jampa | Chief Technology Officer |
| Shereen Solaiman | Chief People Officer |
| Brian Donnelly | Chief Commercial Officer |
| Dale Muzzey | Chief Scientific Officer |
| Matthew Scalo | Senior Vice President of Investor Relations |
| Patrick Burke | Executive Vice President of Corporate & Business Development |
| Paul J. Diaz | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 20, 2026 | 8-K | Current Report |
| Oct 09, 2026 | 8-K | Current Report |
| Sep 22, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 17, 2026 | 4 | Filing |
| Sep 17, 2026 | 3 | Filing |
| Sep 16, 2026 | 8-K | Current Report |
| Sep 08, 2026 | 4 | Filing |
| Sep 04, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Myriad Genetics
| Country | United States |
| IPO Date | Oct 6, 1995 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,700 |
| CEO | Samraat S. Raha |
Contact Details
322 North 2200 West Salt Lake City,
Utah 84116 United States
Stock Details
| Ticker Symbol | MYGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000899923 |
| CUSIP Number | 62855J104 |
| ISIN Number | US62855J1043 |
| SIC Code | 2835 |
Add to Watchlist
Select watchlists to add or remove MYGN